Aurobindo Pharma increases stake in China JV to 50%
Aurobindo Pharma's Dutch arm buys 20% more in China's Luoxin Aurovitas for $5M, aiming for 100% ownership by 2029 to scale up inhalation product manufacturing. Read the full strategic move.
Aurobindo Pharma's Dutch arm buys 20% more in China's Luoxin Aurovitas for $5M, aiming for 100% ownership by 2029 to scale up inhalation product manufacturing. Read the full strategic move.
Ajanta Pharma partners with Biocon to distribute generic semaglutide in 26 Asian and African markets. The move targets the booming GLP-1 market post-patent expiry, leveraging Ajanta's strong distribution network.
JioHotstar's new series 'Pharma' ignites public debate on drug pricing, ethics, and accessibility in India's healthcare system. Read the full analysis.
India's pharmaceutical industry gears up for a critical 5-year phase from 2026, aiming to become a $500 billion innovation hub by 2047. Learn how it plans to tackle challenges and seize opportunities.
UST and IIT Madras Incubation Cell sign MoU to accelerate healthcare startups. 'Pitch to Win: Pharma 4.0' challenge sees 90+ entries. Winners get funding up to Rs 45 lakh. Read more.
CGST Rohtak arrests Sonipat pharma trader Pawel Garg for alleged GST evasion of Rs 21.30 crore on sales of Rs 118.49 crore. Raid uncovers unaccounted transactions. Read the full details.
National Award-winning actor Rajit Kapur discusses his return to Malayalam cinema with the medical drama 'Pharma', his role as Dr. Rajiv Rao, and the rise of South Indian OTT content.
Bangladesh's pharma firms have a 2-year head start over Indian giants like Dr Reddy's in exporting generic semaglutide. Delhi HC allows exports, but domestic sales wait until 2026. Explore the competitive landscape.
Nivin Pauly's 'Pharma', Malayalam's first medical drama web series, is now streaming. Our review explores its gripping plot, stellar cast, and why it's a binge-worthy thriller. Watch now!
Sun Pharmaceutical shares fell over 3% after a US FDA inspection at its Baska plant. The inspection concluded with 3 observations. Get the full details on the market impact and company's response.
Malayalam star Nivin Pauly headlines 'Pharma', a hard-hitting web series on the dark side of the pharmaceutical industry. Premieres December 19, 2025, on JioHotstar in 5 languages.
Odisha CM Mohan Majhi positions state as top pharma & medical devices investment destination. New policy & parks attract Rs 7,043 crore proposals, 45 MoUs signed. Read more.
Odisha CM Mohan Charan Majhi launches the Pharmaceutical and Medical Devices Policy 2025, aiming to attract investments and create jobs. The state announces two dedicated industrial parks. Read more.
Corona Remedies IPO subscription starts Dec 8. Price band ₹1008-1062, aims to raise ₹655 cr. Grey market premium signals strong investor interest. Details inside.
Corona Remedies' ₹655 crore IPO opens today. With a price band of ₹1,008-₹1,062 and a strong GMP, analysts give a 'Subscribe for long term' rating. Key dates and details inside.
Odisha's new Pharma & Medtech Policy 2025 aims to make the state a strategic hub for healthcare manufacturing. The policy includes plans for dedicated industrial parks and a roadmap aligned with India's 2047 vision. Read more.
Himachal Pradesh's pharmaceutical hub is in turmoil as 38 firms lose WHO-GMP certification, raising serious quality concerns. Discover the causes and impact.
Nivin Pauly's OTT debut 'Pharma' trailer reveals a medical rep exposing dangerous drugs. The series premieres on JioCinema December 19 in 7 languages. Read more.
Hyderabad's Laurus Labs plans aggressive CDMO growth, targeting 50% of revenue in five years. CEO Dr. Satyanarayana Chava reveals strategy focusing on cell & gene therapy and global expansion. Read more.
Granules India's US subsidiary, Granules Consumer Health LLC, successfully cleared a USFDA GMP inspection with zero observations. This marks a significant achievement for the Hyderabad-based pharma major's OTC product operations in America.
Corona Remedies IPO opens Dec 8, 2025, to raise ₹655.37 crore. Check price band, GMP, financials, and key dates for this pharma company's public issue.
Indian stock markets opened strong on December 3, 2025, with Nifty crossing 25,400. Key stocks like TCS and Sun Pharma in focus. Read for full analysis and trading cues.
Wockhardt's share price surged over 6% after the USFDA accepted its New Drug Application for Zaynich, a novel antibiotic. Discover the details and market impact.
Sun Pharma introduces its global biologic Ilumya for moderate-to-severe plaque psoriasis in India. Backed by Phase-3 data, it offers long-lasting clearance with a strong safety profile. Learn more about this targeted therapy.
Indian API manufacturers are shifting to high-value contract development, targeting $22-25 billion market by 2035 as global pharma diversifies from China. Read about the growth trajectory.
Speciality chemical makers supplying pharma CDMOs post 7% sales growth, outpacing non-pharma peers. Strong margins and global shifts fuel this resilient sector. Read more.
November 2025 witnessed 9 IPOs with 12 listings. Groww leads with 58.85% gains while experts warn of investor fatigue and unrealistic valuations. Read full analysis.
Sudeep Pharma shares surged 33.78% in market debut, exceeding expectations. Analysts advise partial profit booking while maintaining long-term optimism. Read expert views on buy/sell strategy.
Sudeep Pharma shares surged 23% in stock market debut today, outperforming grey market expectations. The ₹895-crore IPO was subscribed 93.71 times. Read full analysis.
Sudeep Pharma makes its stock market debut today. With a GMP of ₹121, the IPO is set for 20% listing gains after a blockbuster 93.72 times subscription. Get all the live details.